Recent advances in whole-genome technologies have supplied the fi eld of cancer research with an overwhelming amount of molecular data. Improvements in massively parallel sequencing approaches have led to logarithmic decreases in costs, and so these methods are becoming almost commonplace in the analysis of clinical trials and other cohorts of interest. Furthermore, whole-transcriptome quantifi cation by RNA sequencing is quickly replacing microarrays. However, older chip-based methodologies such as comparative genomic hybridization and singlenucleotide polymorphism arrays have benefi ted from this technological explosion and are now so accessible that they can be employed in increasingly larger cohorts of patients. The study of breast cancer lends itself particularly well to these technologies. It is the most commonly diagnosed neoplasm in women, giving rise to nearly 230,000 new cases each year. Many patients are given a diagnosis of early-stage disease, for which surgery is the standard of care. These attributes result in excellent availability of tissues for whole-genome/transcriptome analysis. The Cancer Genome Atlas project has generated comprehensive catalogs of publically available genomic breast cancer data. In addition, other studies employing the power of genomic technologies in medium to large cohorts were recently published. These data are now publically available for the generation of novel hypotheses. However, these studies diff ered in the methods, patient cohorts, and analytical techniques employed and represent complementary snapshots of the molecular underpinnings of breast cancer. Here, we will discuss the convergences and divergences of these reports as well as the scientifi c and clinical implications of their fi ndings.
Introduction
Breast cancer is the most common malignancy in women, totaling nearly 230,000 new cases in 2012 [1] . Owing to improvements in screening, many patients are identifi ed before disease dissemination and can undergo surgical resection of the primary tumor. Despite early detection, surgery, and adjuvant therapy, a fraction of patients ultimately recur with metastatic disease. Th ere are three clinical subtypes of breast cancer that diff er on the basis of the expression of estrogen receptor-alpha (ER-α), progesterone receptor (PR), and the HER2 oncogene. Th ese clinical markers can predict the response to antiestrogens and anti-HER2 therapies with a reasonable degree of accuracy [2, 3] . Via gene expression profi ling, several 'molecular' subtypes (termed the PAM50 intrinsic subtypes) of breast cancer have been characterized [4] .
Th ese include luminal A (high expression of ER, sensitive to anti-estrogens, and good prognosis), luminal B (lower expression of ER, less responsive to anti-estrogens, high proliferative rate and histological grade, and poor prognosis), HER2-enriched (containing most HER2 geneamplifi ed tumors and a subset of tumors lacking HER2 amplifi cation), basal-like (mainly tumors not expressing HER2 or ER or PR, high relapse rate, and responsive to chemotherapy), and claudin-low (tumors with a pronounced cancer stem cell-like component, resistant to chemotherapy, and poor prognosis) [4, 5] . Although molecular stratifi cation has improved risk prediction and clinical trial design, the genomic alterations and therapeutic targets (in addition to ER, PR, and HER2) underlying these subtypes have not been established.
Th e high rate of surgical resection in breast cancer has resulted in readily available tissues for high-throughput genomic analyses such as massively parallel sequencing (MPS), expression microarray, and comparative genomic hybridization (CGH) . Th e availability of tissue coupled with the rapid acceleration of these technologies and their dwindling cost has allowed the construction of comprehensive catalogs of the genomic architecture of breast cancer in large sample sizes [6] [7] [8] [9] [10] [11] . Combined, these data have provided a catalog of somatic alterations in more than 3,500 breast tumors. Th ese results confi rm the somatic mutation landscape, where few genes are mutated in many tumors (for example, TP53) whereas many genes are recurrently mutated in few tumors. However, these diverse mutations can often be organized into several frequently mutated path ways. Th ese data provide novel insights into the patho genesis and classifi cation of the disease, driving forward molecular analyses to discover new treatments.
Summary of genomic data in breast cancer
Th e largest of these studies interrogated copy-number alterations (CNAs) by SNP-chip and gene expression profi les by microarray in nearly 2,000 tumors repre senting all major subtypes of breast cancer [9] . Aside from identifying recurrent CNAs, the authors integrated gene expression and CNA data to determine the impact of inherited and somatic gene copy number on gene expression levels. CNAs and single-nucleotide polymorphisms (SNPs) associated with the genes in the altered region (termed cis loci) as well as those outside the altered region (trans loci) were identifi ed. Approximately 40% of the tumor transcriptome was associated with the presence of SNPs or CNAs, acting either in cis or in trans. Somatic CNAs, as opposed to SNPs and germline CNAs, had the strongest association with gene expression architecture in breast tumors. Th e authors identifi ed, among other alterations, novel deletions in PPP2R2A among luminal B tumors and MAP2K4 deletions (previously identifi ed in luminal breast cancer cell lines [12] and multiple tumor types, including breast [13] ) in ER + tumors, suggesting that these genes may be tumor suppressors. However, molecular evidence for tumor suppression by either gene has not been demonstrated.
Th e authors proposed, on the basis of gene expression and CNA data, 10 novel subclassifi cations of breast cancer [9] . Several of these clusters overlapped considerably with the PAM50 intrinsic subtypes [4] . However, the integration of CNA data coupled with the large sample size allowed more intricate dissection of some heterogeneous sub types, such as basal-like breast cancer (primarily contained in one cluster, with losses in chromo some 5 and gains at 8q, 10p, and 12p). Th ese subtypes include a previously identifi ed [14, 15] poorprognosis luminal group containing amplifi cation of 11q13/14, which includes CCND1 and other potential drivers. Of note, the authors also identifi ed a 'CNAdevoid' subgroup which had good prognosis and was characterized by high genomic stability, a fl at copynumber landscape, and signatures of an adaptive immune response [9] . Finally, the authors employed bioinformatic approaches to ascribe biological underpinnings to the profi les observed in each of these subtypes. Th e categories of molecular processes identifi ed in several of the clusters paralleled those established previously in triple-negative breast cancer (TNBC) [16] , reaffi rming the diversity of this clinical subtype. Th is study also identifi ed rare but recurrent CNAs in therapeutic targets such as amplifi cation of IGF1R, KRAS, and EGFR.
Shah and colleagues [7] used MPS to describe the somatic mutational landscape in 104 TNBCs. TNBC accounts for approximately 15% of breast cancers, representing a heterogeneous and highly virulent disease subtype. An advantage of this study, despite its smaller size, was its focus on TNBC, which allowed the authors to make inferences about the diversity of its clonal evolution. TNBCs showed a continuous distribution of numbers of CNAs and point mutations per tumor, which were not associated with one another. Th is suggests that the mechanisms and environmental factors contributing to the development and progression of breast tumors through the generation of CNAs and somatic mutations are distinct. Also, by integrating copy-number and deep re-sequencing data, the authors calculated allele frequencies for thousands of identifi ed mutations. Th ey examined the mutation-frequency distribution in each tumor, fi nding that some TNBCs have only a few 'peaks' of allele frequencies but that others have more than 15 peaks. Th us, some tumors consisted of a heterogeneous multi-clonal pool of transformed cells, whereas some consisted of only one or two dominant transformed clones. Th e nature and number of these clones may have implications for targeted therapies. For instance, therapeutic targeting of lesions present in only one of fi ve theoretical clonal populations may not be suffi cient to induce a clinical response. By organizing aberrations into targetable pathways and prioritizing by their clonal frequency, the authors concluded that alterations in several known drivers, including PTEN, PIK3CA, and TP53, demonstrated the highest degree of clonal frequency and are likely the initiating or 'founder' lesions in TNBC. Th e authors reported that 20% of tumors contained at least one somatic mutation that is currently targetable, but these mutations were not always commonly associated with TNBC or breast cancer in general (for example, one case contained a V600E BRAF mutation). Similar fi ndings supporting the notion of dominant subclones composed of only a handful of driver mutations were reported shortly thereafter by Nik-Zainal and colleagues [17] .
In a study that focused on ER + breast cancer, Ellis and colleagues [8] performed whole-genome sequencing of 46 tumor-normal pairs and an additional 31 exomes, followed by targeted re-sequencing in an additional 240 tumors. Th is study was unique in that it incorporated therapeutic response into its design. Th e tumors analyzed were from patients treated for approximately 4 months with aromatase inhibitors (AIs). Drug-induced changes in tumor cell proliferation were measured by Ki67 immunohisto chemistry (IHC) before and after therapy. Th e proportion of Ki67 + cells was used as a biomarker for response to estrogen deprivation as previously estab lished [18] [19] [20] . In addition to identifying recurrent muta tions in genes not previously implicated in breast cancer, including TBX3, RUNX1, LDLRAP1, MYH9, AGTR2, STMN2, SF3B1, and CBFB, the authors identifi ed mole cular markers for response to an AI. For example, mutations in TP53, a hallmark of basal-like breast cancer and TNBC, were enriched in luminal B tumors and were associated with a lower anti-pro liferative response. However, it is unclear whether TP53 plays a direct role in resistance to anti-estrogen therapy or whether it is a marker of a less hormone-driven tumor (that is, basal-like). Pathway analysis [21] of the mutation data identifi ed several cell signaling networks associated with anti-proliferative response to an AI, such as the MAPK, FYN (an Src-family kinase), and MYC pathways. Both the MYC and MAPK pathways have been reported to be highly activated in (ER − ) basal-like tumors and cell lines [22, 23] . Finally, the authors also reported mutations in the HER2 gene in the absence of gene amplifi cation. A recent study documented that these are gain-of-function mutations and are sensitive to small-molecule HER2 tyrosine kinase inhibitors [24] .
Banerji and colleagues [10] sequenced the exomes of 103 primary tumors and an additional fi ve cancers by whole-genome sequencing. Seventeen cases were sequenced by both methods. Th e authors identifi ed six recurrently mutated genes within this cohort: CBFB, TP53, PIK3CA, AKT1, GATA3, and MAP3K1. All of these, with the exception of CBFB, have been previously identifi ed as recurrently mutated in breast cancer. CBFB, encoding core-binding factor beta subunit, was mutated in four ER + tumors. CBFB is a heterodimeric partner with the RUNX family of transcription factors. Th is transcriptional complex appears to be frequently inactivated as a hemizygous deletion of RUNX1 at the genomic level co-occurred with CBFB mutations. In addition, several cancers with homozygous deletions of RUNX1 were identifi ed. CBFB and RUNX1 mutations were also identifi ed by Ellis and colleagues [8] and in Th e Cancer Genome Atlas (TCGA) study (below), suggesting that disruption of CBFB/RUNX1 function is involved in breast cancer progression. Like Ellis and colleagues [8] , the authors identifi ed mutations in HER2 gene in tumors without HER2 amplifi cation. Finally, the authors identifi ed an in-frame genomic translocation event between MAGI3 and AKT3 [10] . Among 235 additional tumors, nine cases (3.8%) with MAGI3-AKT3 fusions were identifi ed. Th ese fusions retained the kinase domain of AKT3 while disrupting the pleckstrin homology and PTEN-binding domains of AKT3 and MAGI3, respectively. When expressed in breast cancer cells, the fusion transcript resulted in constitutive AKT phosphorylation and activity, rendering the cells sensitive to an ATP-competitive AKT inhibitor. However, these fusions have not yet been identifi ed in other sequencing studies.
Stephens and colleagues [6] sequenced 100 primary breast cancers by using whole-exome MPS. Similar to the studies by Ellis and colleagues [8] and Curtis and colleagues [9] , recurrent inactivating mutations and deletions in the MAP3K1 and MAP2K4 genes were identifi ed. Th e mutation patterns of ARID1B, CASP8, MAP3K13, NCOR1, SMARCD1, and CDKN1B (p27) suggested that these genes may also be tumor suppressors. Several of these genes, including MAP3K1, CASP8, and TBX3, are recessive cancer genes previously identifi ed in genomewide association studies [25, 26] . Interestingly, germline mutation of TBX3 causes ulnar-mammary syndrome, which includes, among other defects, failure of mammary gland development [27] .
Th e TCGA is a comprehensive collection of copynumber (SNP-chip), microarray, RNA-sequencing, MPS, clinical, and proteomic data across multiple cancer types [11] . Approximately 450 breast cancers with data from all methods were compiled. Th e TCGA confi rmed the presence of previously identifi ed mutations in TBX3, RUNX1, and CBFB, including subtype-specifi c associations of PIK3CA, MAP3K1, and GATA3 mutations with ER + and luminal A tumors. Additionally, AFF2, PIK3R1, PTPN22, PTPRD, NF1, SF3B1, and CCND3 were found to be recurrently mutated. Interestingly, a comparison of the breast cancer and ovarian TCGA data demonstrates that, from a molecular perspective, basaltype breast cancers more closely resemble ovarian serous carcinomas than luminal breast cancers do. Furthermore, basal-type breast cancers, despite having the lowest percentage of PIK3CA mutations, exhibit the highest PI3K pathway activity as measured by phospho protein and gene expression signatures. Th ese fi ndings may be due to deletions in tumor suppressors -such as PTEN and INPP4B -that negatively regulate the PI3K pathway. Mutual exclusivity module analyses demon strated that the receptor tyrosine kinase (RTK)-PI3K and p38-JNK pathways are aff ected in almost 80% of breast carcinomas, providing a clear set of common targetable pathways despite the enormous genetic heterogeneity. Th e greatest contributions of the TCGA study are the integration of multiple data types, including clinical annotation and proteomic data, and the accessibility of these data to outside investigators. As such, the TCGA data represent an excellent source for the generation of novel hypotheses and some access to limited retro spective clinical data which can be accessed through the cBio web portal [28] . Th is data portal has been constructed to allow all investi gators, including those not used to handling and analyzing high-dimensional data, to easily interrogate genes and pathways of interest. However, the retrospective nature of the TCGA project and its use of tumors not necessarily linked to specifi c clinical trials, in which the outcome of therapy can be assessed rigorously, limit the ability of the TCGA to establish whether the genomic data can 'predict' the action of the current treatment standards (that is, anti-estrogens or chemotherapy). Nonetheless, the TCGA project provides a 'blueprint' that in some form should be part of the molecular analyses linked to investigational clinical trials with novel drugs and combinations, particularly where a diagnostic biomarker for patient selection is lacking.
Finally, Nik-Zainal and colleagues [17, 29] sequenced the complete genome of 21 breast cancers. Th ese authors identifi ed driver mutations in many of the genes mentioned above, but the major contribution of these articles was to use whole-genome data to elucidate mutational processes in breast cancer. Indeed, they identifi ed at least fi ve diff erent mutational processes, such as C>T mutations at TpCpX tri-nucleotides. Clustering of the samples based on these mutational processes identifi ed two major groups, separated by BRCA1/BRCA2 status. Th e signifi cant heterogeneity in the mutational processes occurring in breast cancer suggests similar heterogeneity in the defects in repair mechanisms in these tumors. With the development of PARP inhibitors, defective DNA repair mechanisms are emerging as therapeutic targets. Exploitation of such targets in breast cancer will require the identifi cation of the defective processes underlying each of these fi ve categories and the development of drugs that target these alterations.
Th ese landmark studies each catalogued the molecular lesions in breast cancer by using diff erent sets of patients, technologies, and methods of analysis (Table 1) . Novel insights gleaned from these data into the pathogenesis of breast cancer will be important for our understanding of the basic biology of this disease. However, what does this mean for breast cancer patients seeking standard care or a clinical trial or both? Do the results of these studies and the massive amount of data generated portend novel thera pies that can change the natural history of the disease? It is somewhat reassuring, but not surprising, that striking similarities in recurrently mutated or altered genes were identifi ed among the studies (Figure 1 ). Further more, many commonly altered genes identifi ed were previously impli cated in breast or other cancers, attesting to the visionary work of those investigators who previously identifi ed them in the absence of MPS technologies. Th e power of the studies reviewed here lies not in single gene alterations but in the ability to combine less commonly altered genes into pathways on the basis of known biology and function. From these data, pathways not previously implicated in breast cancer can now be explored to determine whether they are associated with exploitable therapeutic vulnerabilities.
Implications for breast cancer classifi cation and treatment
A key direction resulting from the studies presented is a more specifi c and diverse classifi cation of breast cancer into multiple genome-driven subtypes, each potentially with a personalized treatment approach. Breast cancer is currently treated on the basis of three clinical markers: ER, PR, and HER2. Breast cancers expressing ER or PR are more likely to be responsive to anti-estrogen therapy. However, a signifi cant proportion of HR + tumors exhibit de novo or acquired resistance to endocrine therapy. Th ese tumors, termed 'luminal B' , are hyper-proliferative and less well diff erentiated and benefi t from chemotherapy in addition to anti-estrogens. Several approaches have been used to identify luminal B tumors, such as the PAM50 clinical assay [4] , the Oncotype DX algorithm [30] , and IHC markers such as high Ki67, HER2 overexpression, absence of PR, or low ER [18, 31] . Th is separation of luminal B from the less aggressive luminal A counterpart, though not yet optimal, is important for the selection of patients with ER + luminal B breast cancer into clinical trials of combinations of anti-estrogens with novel therapies. Signifi cant data support the notion that the distinction between luminal A and B tumors may be more of a continuum of proliferation, diff erentiation, and accompanying HER2 expression, leading to diffi culty in clinical cutoff s and decision-making.
Alterations in several genes and pathways were identifi ed as being linked to the luminal A/B phenotype in multiple studies. Th ese include activating PIK3CA mutations and deletions or inactivating mutations within the JNK pathway (MAP2K4, MAP3K1, and possibly STMN2) in luminal A tumors and PPP2R2A deletions in luminal B tumors. At this time, several prospective randomized clinical trials of anti-estrogens with or without PI3K pathway inhibitors in patients with ER + / PIK3CA mutant breast cancer are ongoing. Th e initial phase I study of the p110α-specifi c inhibitor BYL719 was limited to patients with tumors harboring PIK3CA-activating mutations. Results from this study have already shown clinical activity of the single agent in patients with PIK3CA-mutant metastatic ER + breast cancer [32] . Results of these trials should shed light on the role of these mutations in anti-estrogen-treated luminal breast cancers. In the case of MAP2K4 and MAP3K1 alterations, which putatively inactivate the JNK pathway, uncovering a therapeutic role for targeting tumors with these lesions could be challenging: they tend to occur in tumors with the best prognosis, many of which are cured with surgery and adjuvant endocrine therapy.
Amplifi cation or high expression (or both) of HER2 is a predictive marker for response to HER2-targeted therapies [33, 34] . However, some breast cancers display gene expression patterns consistent with HER2 overexpression (that is, the HER2-enriched molecular subtype of the PAM50 classifi er [4] ) in the absence of HER2 gene amplifi cation as measured by fl uorescence in situ hybridization. Several of these studies have reaffi rmed this discrepancy and also have led to the discovery of novel HER2 mutations in the kinase and juxtamembrane regions, which were recently established as possible drivers in non-HER2-amplifi ed breast cancer [24] . Breast cells transformed with these mutations were sensitive to HER2 kinase inhibitors, such as lapatinib and neratinib. Th us, it is increasingly apparent that there may be several subgroups of HER2-driven breast cancer. Th is could poten tially expand the number of patients in whom HER2-targeted combinations are eff ective.
TNBC, often associated with basal-like gene expres sion, lacks expression of ER, PR, and HER2 and repre sents a heterogeneous group of tumors at clinical, histo pathological, and molecular levels [11, 16, [35] [36] [37] . Although TNBCs, as a group, are generally more sensitive to conven tional chemotherapy, they also demonstrate higher relapse rates and poorer survival compared with other breast cancer subtypes [38] . Clinical studies have shown good responses with poly (ADP-ribose) polymerase (PARP) inhibitors in TNBC with BRCA gene defi ciency [39, 40] . Th e DNA cross-linker cisplatin has also shown remarkable activity in patients with BRCA1 mutant TNBC but its role in TNBC with wild-type BRCA1 is less clear [41] . Th e studies reviewed here did not identify possible therapeutic sensitivities of TNBC or basal-like breast cancer [6] [7] [8] [9] [10] [11] . However, the high degree of genomic rearrangement identifi ed in this subtype supports the further examination of agents targeting the DNA damage response and repair mechanisms, which are defective in some TNBCs [7, 11] . Nonetheless, many unanswered questions about how future clinical trials should incorporate targeted therapies in TNBC remain.
Gene signatures such as Oncotype DX [30] and genomic grade index [42] have been less useful in identifying diff erent risk categories within TNBC than within ER + breast cancer. A recent study identifi ed biologically diverse TNBC clusters by using transcriptome datasets from 21 independent studies [16] . Th ese clusters were defi ned by DNA damage response genes, mesenchymal features, immune-related genes, and androgen receptor (AR) signaling [16] . Th e 'mesenchymal' cluster overlaps with a previously reported claudin-low breast cancer subtype also characterized by loss of epithelial diff er entiation, an intense immune infi ltrate, and cancer stemlike charac teristics [5, 16] . Using TNBC cell lines and xenografts, Lehmann and colleagues [16] associated these clusters with particular therapeutic vulnerabilities (that is, anti-androgens in the AR luminal cluster, El lis et al. [8] Biopsies from ER + breast tumors undergoing neoadjuvant aromatase inhibitor therapy WGS (n = 46), ES (n = 31), and MRS (n = 240) Recurrent mutations in MAP3K1 pathway in ER + disease with good prognosis; anti-proliferative response to aromatase inhibitor associated with mutational activation of FYN, MAPK, and MYC pathways; recurrent mutations in methyl-and demethyltransferases and AT-rich interactive domain-containing genes; ERBB2 mutations in non-ERBB2-amplifi ed breast cancer Shah et al. [7] Triple-negative breast cancer cases WGS (n = 15), ES (n = 54), CGH (n = 104), and RS (n = 80)
Clonal dominance of PIK3CA, PTEN, and TP53 mutations; intragenic PARK2 deletions in TNBC; 30%-40% of somatic mutations are detectable at the RNA level.
Curtis et al. [9] Unselected primary breast tumors CGH (n = 1,992) and MA (n = 1,992)
Copy-number alterations infl uence gene expression in over 40% of the breast cancer genome; deletions in PPP2R2A, MTAP, and MAP2K4; integrated copy-number and microarray data defi ned 10 unique clusters of breast cancer.
Banerji et al. [10] Unselected primary breast tumors WGS (22) and ES (103) Recurrent mutations in CBFB and RUNX1; recurrent MAGI3-AKT3 fusions which are sensitive in vitro to AKT ATP-competitive inhibitors
Stephens et al. [6] Unselected primary breast tumors ES (n = 100) Novel recurrent mutations in AKT2, ARID1B, CASP8, CDKN1B, MAP3K1, MAP3K13, NCOR1, SMARCD1, and TBX3
The Cancer Genome Atlas [11] Unselected primary breast tumors MA (n = 547), DNA-methylation array (n = 802), CGH (n = 773), MIRS (n = 697), RPPA (n = 403), and ES (n = 507)
Luminal breast cancer is most heterogeneously mutated subtype; basal-like breast cancer molecularly resembles serous ovarian carcinoma; mutation patterns consistent with the other studies; convergence of genetic and epigenetic alterations into four primary subtypes of breast cancer CGH, comparative genomic hybridization; ER, estrogen receptor; ES, exome sequencing; MA, microarray; MIRS, microRNA-sequencing; MRS, mutation recurrence screening; RPPA, reverse-phase proteomic array; RS, RNA sequencing; WGS, whole-genome sequencing.
cisplatin and other DNA damaging agents in the DNA damage response subgroup, and PI3K pathway inhibitors in the mesen chymal genes cluster). Th e use of these expression signa tures for treatment selection and prediction of response remains to be determined. Importantly, many of these subtypes or TNBC clusters appear analogous to those described by Curtis and colleagues [9] . Many alterations identifi ed in the studies reviewed here lie in pathways that have been previously explored for drug development. Perhaps the largest challenge to developing new therapeutics against these commonly altered pathways lies in understanding the biological functionality of these mutations. Is the alteration a driver of an oncogenic phenotype? Th e presence of an alteration does not imply oncogene dependence or therapeutic sensitivity. Does the mutation confer gain-of-function, loss-of-function, or a new functionality altogether? Support for clinical targeting of these alterations will require extensive in vitro and in vivo experimentation to understand whether and how the mutation functions biologically.
Implications for clinical trials and care
Th e wealth of data generated in the context of the studies presented should pave the way for additional genotypedriven trials with targeted therapies. Potential markers of sensitivity and resistance to targeted agents can be tested at the bench on the basis of these fi ndings. However, the use of these biomarkers in investigational clinical trials must be approached cautiously. For instance, should only those patients harboring a tumor with mutations in the PI3K pathway be considered for trials with PI3K inhibitors? Although preclinical data support this notion, the complexity of the cancer genome as demonstrated by the reviewed studies may circumvent this simplistic approach. Patients who may benefi t from the targeted therapy but lack (known) lesions in the targeted pathway may be missed on the basis of a lack of comprehensive knowledge of all the molecular lesions dysregulating such a pathway. Alternatively, pathway activation without direct mutation may portend a more plastic target, less addicted to the pathway's output and thus more able to evade inhibition.
Another important implication for clinical trials and biomarker studies can be drawn from the study by Shah and colleagues [7] , who examined clonal frequency of genomic alterations in TNBC. Given the regional heterogeneity present in the tumors, also demonstrated in other studies [29, [43] [44] [45] [46] , therapeutic target identi fi cation becomes challenging. Sampling of the tumor performed from a cross-section of the entire specimen likely gives the best representation of all the lesions and alterations present [46] . Th is can be best achieved from surgical specimens, which are not always available for research purposes. Use of the primary diag nostic biopsy in patients with metastatic breast cancer enrolled in a clinical trial may yield signifi cant discrepan cies between the primary and metastatic lesions [47] . Although core biopsies of metastatic lesions are increasingly being performed over fi ne-needle aspirates (FNAs), the relatively small region of tumor in a core biopsy may still miss a signifi cant percentage of the clonal lesions present in cancer as a whole. Th e clonal lesions may be important in overall response, as recently was experimentally demonstrated in colorectal cancer [45] . Such issues may be overcome by multiple biopsies or by simultaneous sampling of circulating tumor DNA [48] [49] [50] . [7] , Curtis et al. [9] , Banerji et al. [10] , Stephens et al. [6] , and The Cancer Genome Atlas (TCGA) [11] . Deleted (D) genes are in blue, mutated (M) in green, and amplifi ed (A) in red.
In the course of clinical trials of targeted agents, a frequently reported observation is the single patient with an extraordinary response. Examples of such case reports include EGFR inhibitors erlotinib and gefi tinib and the ALK inhibitor crizotinib in non-small cell lung cancer [51, 52] , vemurafenib in melanoma [53] , and everolimus in bladder cancer [54] . Th ese cases present a unique opportunity to identify genomic biomarkers of sensitivity and, in principle, should lead to genotype-specifi c phase II studies in which the initial observation can be validated. Positive genotype-specifi c trials, like those that led to the approval of crizotinib in EML4-ALK fusionpositive NSCLC [55, 56] , can rapidly lead to drug approval. For example, trials with the TORC1 inhibitor everolimus limited to patients with mutations in TSC1/2 and mTOR are being developed.
Th e increased availability of Clinical Laboratory Improve ment Amendments (CLIA)-certifi ed MPS at academic centers and commercial sources is presenting patients and oncologists with new treatment options and dilemmas. Previously identifi ed mutations in 'targetable' genes that are known to be functional will be identifi ed, but drugs directed against these lesions may not yet be approved for use in breast cancer. Furthermore, some mutations will be variants of unknown signifi cance (that is, mutations not previously observed in genes of interest). Tumor heterogeneity will lead to identifi cation of mutations that are clearly not in all tumor cells. Cancers will present with multiple 'actionable' targets, but the key driver of tumor progression may not be apparent. A plausible example is that of a patient who has metastatic TNBC and good performance status and who has exhausted all standard of care options. While being considered for enrollment in a chemotherapy trial at a National Cancer Institute (NCI)-designated cancer center, tissue from a recent metastatic biopsy is submitted for DNA extraction and MPS of approximately 300 known oncogenes and tumor suppressors. Th e assay identifi es mutations in TSC1 and PIK3CA as well as EGFR and CDK4 gene amplifi cations. Encumbered by the molecular data, this patient could consider treatment with an EGFR antibody (for example, cetuximab) or a TORC1 inhibitor (for example, everolimus). However, these drugs have not shown effi cacy in TNBC, although clinical evidence suggests that they may be eff ective against other tumor types with these alterations. In light of the mutation in PIK3CA, a trial with a combination targeting the PI3K pathway could also be considered. At present, many situations like the one described here are happening across cancer care centers in the US. Th is hypothetical scenario portends that (a) patient needs and patterns of care will play an important role in the incorporation of 'predictive' genomics to clinical investigation and care and (b) the design and sometimes rigid process of clinical trials may have to adapt by incorporating genomic informa tion at the time of patient eligibility and enrollment.
Finally, casting a wide net to identify the causative lesions by using whole-genome sequencing may be costand labor-intensive and limited by lower depth of coverage. Th e large genomic studies summarized in this review provide a catalog of genes that can be drawn from to assemble targeted capture assays for higher-depth analysis. However, given that most patients in the presented studies were assayed prior to systemic treatment, it is possible that the majority of alterations mediating acquired resistance to targeted therapies remain to be discovered. Th us, the sampling and analysis of tumors at the time of acquired resistance remain a largely unexplored frontier.
Conclusions
In summary, a wealth of integrated molecular data now exists in primary breast cancer. Although the data available are not exhaustive, they provide a framework for biological validation and experimentation that should guide preclinical studies. For those pathways with therapeutic targets currently under clinical investigation, these studies can be used as a catalog of molecular lesions potentially representing biomarkers of response or resistance to treatment. 
